Advertisement Lorus, Genentech announce licensing agreement for IL-17E in cancer - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Lorus, Genentech announce licensing agreement for IL-17E in cancer

Lorus Therapeutics and Genentech, a member of the Roche Group, have entered into a global intellectual property licensing agreement for IL-17E in cancer.

Lorus has discovered IL-17E (also known as IL-25) cytokine that plays a vital role in inflammation and has potent anticancer properties.

Lorus president and CEO Aiping Young said the company’s scientists have discovered the anticancer properties of IL-17E and have patents pending for the use of IL-17E in cancer in the major world markets.

"IL-17E represents a unique immunotherapeutic approach to the treatment of some of the most important cancers, and preclinical data to date shows excellent efficacy with low toxicity; properties that we plan to demonstrate in the clinic in the near future," Young added.

IL-17E was indentified to have anticancer properties against solid tumors, such as human melanoma, pancreatic, colon, lung, ovarian and breast tumour models with low toxicity.